PRVB News and Press, Provention Bio Inc. From 03/16/23

NEW YORK, NY / ACCESSWIRE / March 16, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Seagen Inc. (NASDAQ:SGEN)'s sale to P...

2023-03-15 13:54:03 ET Provention Bio ( NASDAQ: PRVB ) is scheduled to announce Q4 earnings results on Thursday, March 16th, before market open. The consensus EPS Estimate is -$0.43 and the consensus Revenue Estimate is $8.3M Over the last 3 months, EPS estimates have ...

NEW YORK, NY / ACCESSWIRE / March 14, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Seagen Inc. (NASDAQ: SGEN)'s sale to ...

2023-03-13 20:22:57 ET Shares of Provention Bio Inc ( NASDAQ: PRVB ) more than tripled on Monday after Sanofi S.A. ( EPA: SAN ) confirmed plans of buying the biopharmaceutical company that focused on autoimmune diseases. Here’s what we know so far The French healt...

2023-03-13 12:54:16 ET Gainers: Provention ( PRVB ) +258% . Euda Health ( EUDA ) +41% . Calliditas ( CALT ) +31% . Cipher Mining ( CIFR ) +29% . Caleminder ( CMND ) +26% . Bakkt ( BKKT ) +26% . Hut 8 Mining ( HU...

2023-03-13 10:02:38 ET Gainers: Provention Bio PRVB +248% . Caleminder ( CMND ) +38% . Calliditas Therapeutics ( CALT ) +32% . Euda Health ( EUDA ) +22% . Seagen  ( SGEN ) +15% . Losers: Cingulate CING -28...

Provention Bio Cancels Fourth Quarter and Full Year 2022 Earnings Release and Conference Call PR Newswire RED BANK, N.J. , March 13, 2023 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing imm...

2023-03-13 04:33:31 ET Sanofi ( NASDAQ: SNY ) is acquiring Red Bank, N.J.- based diabetes drugmaker Provention Bio ( NASDAQ: PRVB ) for ~$2.9B. Under the agreement, Sanofi will start a cash tender offer to acquire all outstanding shares of Provention for $2...

Provention Bio to Report Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023 PR Newswire RED BANK, N.J. , Feb. 23, 2023 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting an...

Summary PRVB got its teplizumab approved last year. The molecule is a wonderful new addition to T1D therapy; however, it has been in development for decades. Thus, the patent angle worries me. I covered Provention Bio ( PRVB ) in June 2021, when I said that despite a 1...